Pelvic Radiation Disease Association 2026 Networking Event

Thursday 17th September 10am-5pm | thestudio Birmingham

10.00	**Welcome** PRDA Chair, Elaine Burgess PRDA Volunteer - living with PRD
10.15	**Radbone: prediction, prevention and management of radiotherapy related insufficiency fractures** Dr Claire Higham
10.45	**Research into the efficacy of RADA16 in the management of radiation cystitis** Mr Ramesh Thurairaja
11.15	**PRD e-PAQ trial. Results from a pilot study into its use in Sheffield** Prof. Stephen Radley
11.35	**Comfort break**
11.45	**The South West Radiotherapy Late Effects Services: from a patient complaint to a commissioned regional service** Dr Lisa Durrant
12.15	**Hyperbaric oxygen therapy for late radiation tissue injury: its role in symptom management** Dr Clair Wade
12.30	**Between the Navel and the Knees. An award-winning series of sexual function videos** Robyn Bowman CNS Including Project Participants who co-produced the videos
1.00	**Lunch and Networking**

2.00	**Welcome back** PRDA Volunteer, living with PRD
2.10	**Living with HIV and treated for Anal Cancer: an exploratory study using a co-production approach to deliver person-centred care** Dr Emma Hainsworth and Dr Christine Addington
2.30	**A Dietitian Case Study in Pelvic Radiation Disease** Georgina Giebner RD and Susan Vyoral RD
3.10	**Workshops** (choice of one) a) **PRD Best Practice Pathway** – help us to improve it Facilitated by PRDA Trustee Dr Lesley Smith b) **The New Cancer Plan** – how can this support the development of late effects services. Facilitated by Joanna Fairhurst, Senior Programme Manager, West Midlands Cancer Alliance.
3.55	**Plenary** • feedback from workshops • Closing remarks
4.15	**Coffee and chat** (informal networking opportunity)
5.00	**End of meeting**
6.30	**Evening reception**

LinkedIn Pelvic Radiation Disease Association #PRDA26

3-D MATRIX MEDICAL TECHNOLOGY

Bristol Myers Squibb®

3-D Matrix and Bristol Myers Squibb have provided sponsorship funding for this event, but have had no involvement in its development.